Effect of FGF2 on the activity of SPRYs/DUSP6/ERK signaling pathway in endometrial glandular epithelial cells of endometriosis.

article OA: closed CC0 ⤵ 4 in-corpus citations
View on OpenAlex View on PubMed View at publisher
AI-generated summary by claude@2026-06, 2026-06-08

Fibroblast growth factor 2 upregulates SPRY/DUSP6/ERK signaling in endometriosis glandular cells, indicating a positive feedback loop not present in normal cells.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-06, 2026-06-09

This study investigated whether a positive feedback loop involving FGF2 signaling operates differently in eutopic and ectopic endometrial glandular epithelial cells in endometriosis, compared with normal epithelial cells, using FGF2 stimulation, FGF2 neutralizing antibody, and MAPK inhibitors (U0126 and PD98059). FGF2 content, along with protein and mRNA levels of FGF2, FGFR1, ERK1/2/pERK1/2 pathway components, and the regulators SPRYs (Sprouty1/2/4) and DUSP6, increased in eutopic and ectopic cells after FGF2 treatment but decreased after blocking FGF2, while normal epithelial cells showed no significant change. ERK-pathway inhibition produced similar effects with the two inhibitors in normal cells, but the inhibitory effect of PD98059 was significantly weaker than U0126 in eutopic and ectopic cells. This paper is centrally about endometriosis — it examines FGF2-driven SPRYs/DUSP6/ERK signaling and a proposed positive feedback loop in eutopic versus ectopic endometrial glandular epithelial cells in endometriosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

OBJECTIVE: We aimed at exploring the positive feedback loop in eutopic and ectopic endometrial glandular epithelial cells (EuECs and EECs) in endometriosis. MATERIALS AND METHODS: Normal epithelial cells (NECs), EuECs and EECs were treated with fibroblast growth factor (FGF)2, FGF2 neutralizing antibody, mitogen-activated protein kinases (MAPKs) inhibitors U0126 and PD98059. FGF2 protein level was detected by enzyme-linked immunosorbent assay (ELISA). The expressions of FGF2, FGF receptor 1 (FGFR1), extracellular signal-regulated kinase (ERK)1/2/pERK1/2 and Sproutys (SPRYs) (Sprouty1, Sprouty2, Sprouty4) and dual specificity phosphatase 6 (DUSP6) were detected by Western blot. The mRNA levels of FGF2, FGFR1 (FGF receptor 1), SPRYs (Sprouty1, Sprouty2, Sprouty4) and DUSP6 mRNA were detected by RT-PCR. RESULTS: Among treatment groups, the content of FGF2 in EuECs and EECs was significantly higher than that in NECs (p < 0.05). The mRNA and protein levels of FGF2, FGFR1, SPRYs (Sprouty1, Sprouty2, Sprouty4) and DUSP6 in EuECs and EECs were increased after adding FGF2 (p 0.05). The inhibitory effect of PD9805 on NECs was not significantly different from that of U0126 (p > 0.05); however, the inhibitory effects of PD9805 on EuECs and EECs were significantly lower than those of U0126 (p< 0.05). CONCLUSIONS: The positive feedback loop existed in EuECs and EECs, but maybe not in NECs. The results may provide the guideline to treat endometriosis patients.

My notes (saved in your browser only)

Condition tags

mesh:D004715endometriosis

MeSH descriptors

Endometriosis Fibroblast Growth Factor 2 Signal Transduction Antibodies, Neutralizing Antibodies, Neutralizing Butadienes Butadienes Cell Line Dual Specificity Phosphatase 6 Dual Specificity Phosphatase 6 Dual Specificity Phosphatase 6 Endometriosis Endometriosis Endometrium Endometrium Endometrium Epithelial Cells Epithelial Cells Epithelial Cells Female

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (4)

Cited by (4)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:19:49.066213+00:00
License: CC0 · commercial use OK